A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
Indications Encephalopathy; Traumatic brain injuries
Focus Adverse reactions
Sponsors Hope Biosciences

06 Jun 2023 Planned primary completion date changed from 29 Aug 2024 to 31 Dec 2024.
27 May 2022 Planned End Date changed from 29 Aug 2024 to 31 Dec 2024.
27 May 2022 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com